Utility of FDG-PET in immunotherapy: results from a Phase II study of NSCLC patients undergoing therapy with the PD-L1 inhibitor, atezolizumab (MPDL3280A)

Conclusions The utility of FDG-PET in patients with NSCLC on immune blockade therapy appeared to be similar to what has been reported with conventional chemotherapeutic treatments, with early metabolic response predicting subsequent benefit. Baseline whole-body metabolic tumor volume was a strong negative prognostic factor for OS. Summary dual-time-point data did not provide incremental value.

Source: Journal of Nuclear Medicine - May 23, 2016 Category: Nuclear Medicine Authors: Fredrickson, J., Callahan, J., Funke, R., Sanabria, S., Weber, W., de Crespigny, A., Hicks, R. Tags: Lung Cancer I Source Type: research